Holen Sie sich die Stockscreener-App
14.06
1.47%
-0.21
Handel nachbörslich:
14.06
Schlusskurs vom Vortag:
$14.27
Offen:
$14.14
24-Stunden-Volumen:
1.11M
Relative Volume:
1.11
Marktkapitalisierung:
$1.00B
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-4.8651
EPS:
-2.89
Netto-Cashflow:
$23.50M
1W Leistung:
-6.45%
1M Leistung:
-18.73%
6M Leistung:
+66.98%
1J Leistung:
-40.73%
1-Tages-Spanne:
$13.77
$14.48
1-Wochen-Bereich:
$13.77
$15.42
52-Wochen-Spanne:
$6.92
$24.16
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
14.06 | 1.02B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor (NASDAQ:XNCR) Trading Down 7.1%Time to Sell? - MarketBeat
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Xencor SVP Desjarlais sells $1.15 million in shares - Investing.com
What drives Xencor Inc stock priceMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Will Xencor Inc. (XE9) stock remain on Wall Street radar2025 Biggest Moves & Entry Point Strategy Guides - Улправда
Why Xencor Inc. stock attracts global investors2025 Institutional Moves & Low Risk High Reward Ideas - Улправда
VP Desjarlais Files To Sell 73,367 Of Xencor Inc [XNCR] - TradingView — Track All Markets
Can Xencor Inc. stock sustain revenue growth2025 Market Overview & Fast Gain Stock Trading Tips - Улправда
Will Xencor Inc. stock benefit from upcoming earnings reportsJuly 2025 Big Picture & Advanced Technical Analysis Signals - DonanımHaber
How Xencor Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Low Drawdown Trading Techniques - DonanımHaber
Growth Report: Is Xencor Inc. stock ready for breakoutPortfolio Return Report & Free Safe Entry Trade Signal Reports - Улправда
Can Xencor Inc. stock resist market sell offsJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
How supply shortages influence Xencor Inc. (XE9) stockTrade Entry Summary & Free Community Supported Trade Ideas - Улправда
Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga
Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat
Barclays Maintains Xencor (XNCR) Overweight Recommendation - Nasdaq
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases - TipRanks
Xencor Earnings Notes - Trefis
Fundamentals Check: Why Xencor Inc XE9 stock signals breakout potential - moha.gov.vn
Free cash flow per share of Xencor, Inc. – GETTEX:XE9 - TradingView — Track All Markets
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - BioSpace
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent ExtensionWhat's Changed - simplywall.st
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC - MarketBeat
Xencor Granted US Patent Extension of Certain Xtend Antibodies, Expects Additional Royalty Revenue - marketscreener.com
Xencor issued U.S. patent for Xtend Fc domain - TipRanks
Xencor extends Ultomiris royalty term to 2028 with new patent - Investing.com
Xencor extends Ultomiris royalty term to 2028 with new patent By Investing.com - Investing.com South Africa
Is it possible to buy Xencor Inc(XNCR) shares at a good price now? - uspostnews.com
Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Pullback Watch: What momentum indicators show for Xencor Inc stock2025 Sector Review & Smart Swing Trading Alerts - moha.gov.vn
Is Xencor Stock Built to Withstand a Pullback? - Trefis
How Xencor Inc. stock performs in interest rate cycles2025 Geopolitical Influence & Detailed Earnings Play Alerts - Newser
Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc. - MarketBeat
What hedge fund moves indicate for Xencor Inc. (XE9) stockWeekly Earnings Recap & Low Drawdown Investment Strategies - Newser
What momentum indicators show for Xencor Inc. stock2025 Price Action Summary & High Conviction Investment Ideas - Newser
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC) - The Globe and Mail
Its Stock Has Paid Off Big Time For Xencor Inc - setenews.com
Is Xencor Inc. stock a defensive play in 2025Quarterly Profit Review & Daily Growth Stock Investment Tips - Newser
Xencor (XNCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xencor Inc. diskutieren - sharewise.com
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):